Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer: Long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099

Cancer

Volumn 116, Issue 5, 2010, Pages 1210-1217

  Alvarez, Ricardo H ^a   Booser, Daniel J ^a   Cristofanilli, Massimo ^a   Sahin, Aysegul A ^a   Strom, Eric A ^a   Guerra, Laura ^b   Kau, Shu Wan ^a   Gonzalez Angulo, Ana M ^a   Hortobagyi, Gabriel N ^a   Valero, Vicente ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b US Oncology   (United States)

Author keywords

Anthracylines; Breast cancer; CMF regimen; Inflammatory breast cancer; Locally advanced breast cancer; Primary systemic therapy; Taxanes

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METHOTREXATE; PACLITAXEL; TAMOXIFEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; AXILLARY LYMPH NODE; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; SALVAGE THERAPY; SEGMENTAL MASTECTOMY; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNITED STATES;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; TAXOIDS;

EID: 77149154662     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24901     Document Type: Article

References (16)

1. Hortobagyi GN, Singletary SE, Strom EA. Locally advanced breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. Philadelphia: Lippincott Williams and Wilkins; 2000:645-660.
2. Kaufman M, Hortobagyi GN, Goldhirsh A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: and update. J Clin Oncol. 2006;24:1940-1949.
3. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672-2685.
4. Pierga JY, Mouret E, Dieras V, et al. Prognostic value of persisted node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer. 2000;83:1480-1487.
5. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathological tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460-469.
6. von Minckwitz G, Costa SD, Eiermann W, et al. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol. 1999;17:1999-2005.
7. Bear JD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165-4174.
8. Greene FL, Page DL, Fleming ID, et al. eds. AJCC Cancer Staging Manual. 6th ed. Philadelphia: Lippincott-Raven; 2002.
9. Buchholz TA, Strom EA, Oswald MJ, et al. Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy patients with locally advanced non-inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2006;65:1155-1160.
10. Gonzalez-Angulo AM, Walters R, Broglio K, et al. Using response to primary chemotherapy to select postoperative therapy: long-term results form a prospective phase II trial in locally advanced primary breast cancer. Clin Breast Cancer. 2008;8:516-521.
11. Simon R.Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
12. Thomas E, Holmes FA, Smith TL, et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol. 2004;22:2294-2302.
13. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;20:1456-1466.
14. von Minckwitz G, Kummel S, Vogel P, et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst. 2008;100:552-562.
15. von Minckwitz G, Kummel S, Vogel P, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst. 2008;100:542-551.
16. Hennessy BT, Hortobagyi GN, Rouzier R, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastasis following primary chemotherapy. J Clin Oncol. 2005;23:9304-9311.